Citalopram 20mg Capsule (Fluoxetine Hydrochloride)

Adult dosage

Adults 1. Depression 1) Initial treatment: The initial dose is 20mg of fluoxetine hydrochloride orally once daily in the morning. In controlled clinical trials, doses of 20～80mg daily were administered. If no improvement is observed, an increase in dose may be considered after several weeks. Doses exceeding 20mg daily should be administered in 2 divided doses (morning and noon), and the maximum dose of 80mg daily should not be exceeded. The onset of an adequate antidepressant effect may be delayed until 4 weeks or longer after starting treatment. 2) Maintenance/continuation/extended treatment: There are no definitive data on how long patients should be treated with this medicine, but psychopharmacologists recognize that acute episodes of depression require drug treatment for several months or longer. It is not known whether the amount of antidepressant needed to relieve symptoms is the same as that needed to maintain or sustain remission. 2. Bulimia nervosa Administer 60mg of this medicine daily. The daily dose should not exceed 80mg. Measure electrolyte concentrations before starting treatment. 3. Obsessive-compulsive disorder Administer 20～60mg of this medicine daily. The daily dose should not exceed 80mg. 4. Premenstrual dysphoric disorder Administer 20mg of this medicine daily. After 6 months of treatment, reassess whether continued treatment is necessary. Patients with renal and/or hepatic impairment, patients receiving multiple medicines, older adults, and patients with concomitant illnesses: Administer a lower dose or reduce the frequency of administration. Adjust the dose as appropriate according to age and symptoms. Switching from MAO inhibitors used to treat psychiatric disorders When discontinuing an MAO inhibitor used to treat a psychiatric disorder and starting treatment with this medicine, an interval of at least 14 days must be allowed. Conversely, when starting an MAO inhibitor to treat a psychiatric disorder, at least 5 weeks must have elapsed after discontinuing this medicine. Other MAO inhibitors, such as linezolid or methylene blue Patients receiving linezolid or intravenous methylene blue should not start this medicine because of the increased risk of serotonin syndrome. For patients requiring more urgent treatment of a psychiatric condition, including hospitalization or other interventional procedures, consider treatment. If linezolid or intravenous methylene blue must be administered urgently to a patient already receiving this medicine, and no alternative to linezolid or intravenous methylene blue is available, and the benefits of treatment with linezolid or intravenous methylene blue are judged to outweigh the risk of serotonin syndrome in a particular patient, discontinue this medicine immediately and administer linezolid or intravenous methylene blue. Monitor the patient for symptoms of serotonin syndrome for 5 weeks after administration of linezolid or intravenous methylene blue, or for 24 hours after the last dose, whichever occurs first. Treatment with this medicine may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue. The risk associated with administration of methylene blue by non-intravenous routes (oral tablets or local injection) or intravenous administration of this medicine at a dose of 1mg/kg or less is unclear. Nevertheless, clinicians should be aware of the possibility of emergency symptoms of serotonin syndrome with these uses.

This medication is an antidepressant used to treat psychiatric disorders such as major depressive disorder. In particular, for children, adolescents, and young adults (18 to 24 years old), there may be an increased risk of suicidal thoughts or behaviors, so careful judgment by a physician is necessary when prescribing to this age group. This medication should not be administered to patients who are allergic to the drug or its additives, have severe renal impairment, or are taking certain types of medications known as MAO inhibitors. Patients with a history of seizures or high suicidal risk, those with a history of mania or hypomania, or patients with heart disease need special attention when using this medication, and they should consult medical professionals immediately if symptoms worsen or unusual reactions occur. Since this medication is metabolized and excreted in the liver and kidneys, patients with impaired liver or kidney function may require dosage adjustments. Diabetic patients should regularly monitor blood glucose levels as this medication can affect blood sugar control. Patients with elevated eye pressure or at risk of glaucoma should take care as this medication may cause pupil dilation. Common side effects of this medication include headache, nausea, insomnia, fatigue, and diarrhea, while serious allergic reactions, bleeding, or arrhythmias may occur rarely. During the initial treatment or with dosage changes, mental changes such as suicidal thoughts or behaviors, anxiety, restlessness, and aggression may arise, so patients and families should observe symptoms closely. Suddenly stopping this medication can lead to withdrawal symptoms such as dizziness, sensory abnormalities, anxiety, and nausea, so tapering off the dosage gradually as directed by a physician is recommended. There may be interactions with other medications, so it is essential to inform medical professionals about other medications being taken, especially with MAO inhibitors, anticoagulants, certain heart medications, and central nervous system drugs. If pregnant or breastfeeding, careful consideration of the potential impact on the fetus or newborn is warranted, and if breastfeeding, either stopping breastfeeding or using the minimum effective dose is recommended. The safety and effectiveness of this medication in children and adolescents have not been sufficiently established, so its use is not recommended. Elderly patients may have varying risks of side effects based on other underlying conditions or medications, so caution is needed. In cases of overdose, severe symptoms such as nausea, vomiting, seizures, and arrhythmias may occur, which require immediate emergency treatment. This medication should be kept out of the reach of children, and care should be taken not to transfer it to other containers as it may compromise quality.

Headache, nausea, insomnia, fatigue, diarrhea, anaphylaxis reaction, serum sickness, abnormal secretion of antidiuretic hormone, decreased appetite, hyponatremia, anxiety, nervousness, restlessness, tension, decreased libido, sleep disorder, abnormal dreams, depersonalization, elevated mood, happy mood, thought disorder, sexual desire disorder, bruxism, hypomania, mania, hallucinations, agitation, panic attack, suicidal thoughts and behaviors, confusion, attention deficit, dizziness, taste disorder, hypersomnia, drowsiness, tremors, psychomotor agitation, movement disorders, ataxia, balance disorder, tics, seizures, akathisia, serotonin syndrome, memory impairment, blurred vision, pupil dilation, palpitations, ventricular arrhythmia, QT prolongation, flushing, hypotension, vasculitis, vasodilation, yawning, dyspnea, pharyngitis, lung-related events, nosebleeds, vomiting, dyspepsia, dry mouth, dysphagia, esophageal pain, gastrointestinal bleeding, specific hepatitis, rash, urticaria, pruritus, sweating, hair loss, tendency for increased bruising, cold sweats, angioedema, petechiae, phototoxic reaction, purpura, erythema multiforme, arthralgia, myoclonus, myalgia, frequency of urination, dysuria, urinary retention, urinary dysfunction, gynecological bleeding, erectile dysfunction, ejaculation disorder, sexual dysfunction, galactorrhea, hyperprolactinemia, priapism, anxious mood, chills, lethargy, abnormal mood, feeling cold, feeling hot, mucosal bleeding, weight loss, abnormal liver function tests, suicidal ideation, suicidal behavior, fractures, withdrawal symptoms, dizziness, sensory disturbances, sleep disorders, asthenia, agitation, anxiety, tremors, headache, anaphylactoid reaction, progressive systemic reactions, severe skin, kidney, liver, or lung-related reactions, weight loss, growth delay, hyponatremia, changes in platelet function, aplastic anemia, atrial fibrillation, cataracts, cerebrovascular accident, cholestasis jaundice, dyskinesia, eosinophilic pneumonia, epithelial necrosis, erythema multiforme, nodular erythema, exfoliative dermatitis, gynecomastia, cardiac arrest, liver failure, necrosis, hyperprolactinemia, hypoglycemia, immune-mediated hemolytic anemia, renal failure, worsening of movement disorders, optic neuritis, pancreatitis, pancytopenia, pulmonary embolism, pulmonary hypertension, thrombocytopenia, thrombocytopenic purpura, ventricular tachycardia, vaginal bleeding, aggressive behavior, akathisia

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is best to maintain the storage temperature between 1 to 30 degrees Celsius.

Appearance

A hard capsule with a green upper part and a pale yellow lower part, filled with a white to grayish white powder.

Package unit

30 capsules/bottle, 300 capsules/bottle